Clinical Trial on the Methodology of Hysterosalpingography: a Comparative Study (MethodHSG)
6. mai 2026 oppdatert av: Gulseren Polat, Medipol University
Different techniques have been developed to optimize hysterosalpingography (HSG) methodology.
Our aim is to compare the advantages and disadvantages of these three different techniques in terms of both patient satisfaction and clinician's interpretation.
The medical records of the patients who are treated in our hospital between 2020 and 2022 are investigated based on the eligibility criteria.
Studieoversikt
Status
Fullført
Forhold
Studietype
Intervensjonell
Registrering (Faktiske)
251
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
-
Istanbul, Tyrkia (Türkiye), 34214
- Istanbul Medipol University, Medipol Mega University Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
Tar imot friske frivillige
Ja
Beskrivelse
Inclusion Criteria:
- Female patients with infertility
Exclusion Criteria:
- Male patients
- Patients who are diagnosed with menopause
- Patients who do not want to proceed with HSG for diagnosis purposes
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Aktiv komparator: Group 1: Metal Cannula
Applied to 158 infertile women.
While the patient was made to cough forcefully, a tenaculum was gently inserted into the cervix.
A Rubin cannula, de-aired and filled with radiopaque, was placed in the cervical canal.
The speculum was removed.
Traction was applied to the tenaculum to bring the uterus into a straight position, and while radiopaque material was injected under fluoroscopy, the cavity, tubal corneum, isthmus, ampulla, and degree of spillage into the abdomen were visualized.
|
Different techniques of hysterosalpingography (HSG) were applied for 3 groups in parallel.
|
|
Aktiv komparator: Group 2: Active Method Balloon Catheter
Applied to 50 infertile women.
In this case, a balloon catheter was placed from the cervix into the uterine cavity.
A 2cc balloon was inflated.
The uterus was brought to a straight position by applying traction to the balloon catheter, and the cavity, tubal corneum, isthmus, ampulla, and degree of spillage into the abdomen were visualized while radiopaque material was injected under fluoroscopy guidance.
The uterine isthmus was visualized while the balloon was being deflated and withdrawn.
|
Different techniques of hysterosalpingography (HSG) were applied for 3 groups in parallel.
|
|
Aktiv komparator: Group 3: Passive Method Balloon Catheter
Applied to 43 infertile women.
In this case, a balloon catheter was placed from the cervix into the uterine cavity.
A 2cc balloon was inflated.
While the balloon catheter was in the cavity, the tubal corneum, isthmus, ampulla, and degree of spillage into the abdomen were visualized by first injecting radiopaque material under fluoroscopy guidance.
Then, the cavity was visualized while the balloon catheter was being deflated and withdrawn, and the uterine isthmus was visualized.
This procedure was called the passive method balloon catheter method.
|
Different techniques of hysterosalpingography (HSG) were applied for 3 groups in parallel.
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Patient Satisfaction
Tidsramme: Day 1
|
Patients' visual analogue scores (VAS) immediately after the procedure and 30 minutes post-procedure are recorded, respectively. The pain is assessed by the principal investigator. The visual analog scale for pain is a straight line with one end meaning no pain and the other end meaning the worst pain imaginable. The Visual Analogue Scale (VAS) measures pain intensity. The VAS consists of a 10 cm line, with two end points representing 0 ('no pain') and 10 ('pain as bad as it could possibly be'). |
Day 1
|
|
Clinician's Interpretation
Tidsramme: Day 1
|
The interpretation is classified as "clearly evaluated", "partially evaluated" and as "could not be evaluated" by the clinician.
|
Day 1
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Gulseren Polat, M.D., Medipol University
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Generelle publikasjoner
- Pellerito JS, McCarthy SM, Doyle MB, Glickman MG, DeCherney AH. Diagnosis of uterine anomalies: relative accuracy of MR imaging, endovaginal sonography, and hysterosalpingography. Radiology. 1992 Jun;183(3):795-800. doi: 10.1148/radiology.183.3.1584936.
- Preutthipan S, Linasmita V. A prospective comparative study between hysterosalpingography and hysteroscopy in the detection of intrauterine pathology in patients with infertility. J Obstet Gynaecol Res. 2003 Feb;29(1):33-7. doi: 10.1046/j.1341-8076.2003.00068.x.
- Chalazonitis A, Tzovara I, Laspas F, Porfyridis P, Ptohis N, Tsimitselis G. Hysterosalpingography: technique and applications. Curr Probl Diagn Radiol. 2009 Sep-Oct;38(5):199-205. doi: 10.1067/j.cpradiol.2008.02.003.
Hjelpsomme linker
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. januar 2020
Primær fullføring (Faktiske)
31. august 2022
Studiet fullført (Faktiske)
25. april 2026
Datoer for studieregistrering
Først innsendt
25. april 2026
Først innsendt som oppfylte QC-kriteriene
6. mai 2026
Først lagt ut (Faktiske)
13. mai 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
13. mai 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
6. mai 2026
Sist bekreftet
1. mai 2026
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- E-10840098-772.02-275
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
JA
IPD-planbeskrivelse
Data is available upon reasonable request from the principal investigator, Dr. Gulseren Polat.
The results are planned to be published in a medical journal.
IPD-delingstidsramme
Patient recruitment: January 2020 - August 2022
Tilgangskriterier for IPD-deling
When assessed for publications, the editorial office could ask for data if required.
IPD-deling Støtteinformasjonstype
- STUDY_PROTOCOL
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .